X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (36) 36
humans (33) 33
hepatitis c (27) 27
simeprevir (23) 23
antiviral agents - therapeutic use (22) 22
hepacivirus - drug effects (22) 22
hepacivirus - genetics (22) 22
genotype (21) 21
hepatitis c virus (21) 21
gastroenterology & hepatology (20) 20
hepatitis c, chronic - drug therapy (19) 19
pharmacology & pharmacy (16) 16
telaprevir (16) 16
antiviral agents (14) 14
hepatitis c - drug therapy (14) 14
ribavirin (14) 14
tmc435 (14) 14
treatment-naive patients (14) 14
protease inhibitors (13) 13
tmc435 monotherapy (13) 13
plus ribavirin (12) 12
drug resistance, viral (11) 11
drug therapy, combination (11) 11
genetic aspects (11) 11
hepatitis (11) 11
hepatitis c, chronic - virology (11) 11
protease inhibitor (11) 11
ribavirin - therapeutic use (11) 11
simeprevir tmc435 (11) 11
biological response modifiers (10) 10
health aspects (10) 10
interferon (10) 10
once-daily tmc435 (10) 10
proteases (10) 10
sulfonamides - therapeutic use (10) 10
sustained virological response (10) 10
virology (10) 10
antiviral agents - administration & dosage (9) 9
heterocyclic compounds, 3-ring - therapeutic use (9) 9
male (9) 9
medical research (9) 9
medicine, experimental (9) 9
antiviral activity (8) 8
care and treatment (8) 8
female (8) 8
hepatitis c - virology (8) 8
middle aged (8) 8
pegylated interferon (8) 8
sofosbuvir (8) 8
virus-infection (8) 8
adult (7) 7
antiviral agents - pharmacology (7) 7
double-blind (7) 7
gastroenterology and hepatology (7) 7
in-vitro (7) 7
infection (7) 7
infectious diseases (7) 7
mutation (7) 7
phase-iii trial (7) 7
therapy (7) 7
treatment outcome (7) 7
virological response (7) 7
antiviral agents - adverse effects (6) 6
combination therapy (6) 6
digestive system diseases (6) 6
genotype & phenotype (6) 6
hepacivirus - classification (6) 6
interferon-alpha - therapeutic use (6) 6
microbiology (6) 6
peginterferon alpha-2a (6) 6
resistance (6) 6
ribavirin - administration & dosage (6) 6
rna, viral - blood (6) 6
viral nonstructural proteins - genetics (6) 6
aged (5) 5
boceprevir (5) 5
direct-acting antivirals (5) 5
hcv (5) 5
hcv genotype 1 (5) 5
interferon-alpha - administration & dosage (5) 5
pegylated interferon alpha-2a (5) 5
sulfonamides - administration & dosage (5) 5
sustained virologic response (5) 5
treatment failure (5) 5
virus (5) 5
virus diseases (5) 5
abridged index medicus (4) 4
animals (4) 4
chronic hepatitis c (4) 4
cirrhosis (4) 4
double-blind method (4) 4
drug administration schedule (4) 4
drug resistance (4) 4
efficacy (4) 4
genotype 1 infection (4) 4
genotypes (4) 4
hcv genotype-1 infection (4) 4
hepatitis c - diagnosis (4) 4
hepatology (4) 4
heterocyclic compounds, 3-ring - administration & dosage (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Gastroenterology, ISSN 0016-5085, 2012, Volume 143, Issue 5, pp. 1176 - 1178.e6
Journal Article
JOURNAL OF HEPATOLOGY, ISSN 0168-8278, 06/2012, Volume 56, Issue 6, pp. 1247 - 1253
Background & Aims: TMC435 is an investigational, once-daily, oral NS3/4A protease inhibitor currently in phase Ill development for the treatment of hepatitis C... 
PLUS RIBAVIRIN | Genotype | INITIAL TREATMENT | PREVALENCE | COMBINATION | DRUG-USERS | THERAPY | HEPATITIS-C VIRUS | PEGINTERFERON ALPHA-2A | Antiviral | HCV | GASTROENTEROLOGY & HEPATOLOGY | Monotherapy | EAST | EPIDEMIOLOGY | TMC435
Journal Article
Journal Article
Hepatology, ISSN 0270-9139, 12/2018, Volume 68, Issue 6, pp. 2145 - 2157
This open‐label, phase IIa study assessed the safety, pharmacokinetics, and efficacy of direct‐acting antiviral agent (DAA) regimens in patients with chronic... 
INTERFERON | VIRUS | SOFOSBUVIR | 1 HEPATITIS-C | RESISTANCE | ANTIVIRAL ACTIVITY | TMC435 MONOTHERAPY | NAIVE | COMBINATION | GASTROENTEROLOGY & HEPATOLOGY | VIROLOGICAL RESPONSE | Heart | Cirrhosis | Antiretroviral drugs | Antiviral agents | Chronic infection | Safety | Hepatitis C | Pharmacokinetics | Ribonucleic acid--RNA | Patients | Genotypes
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 62, Issue 5, pp. 1047 - 1055
Background & Aims Simeprevir (SMV) is a once-daily (QD), oral hepatitis C virus (HCV) NS3/4A protease inhibitor approved for treatment of genotype (GT) 1 and... 
Gastroenterology and Hepatology | Simeprevir | Chronic | Response-guided | Efficacy | Safety | TMC435 (10/10) | Hepatitis C virus | Sustained virologic response | Protease inhibitor | Genotype 4 | PLUS RIBAVIRIN | MONOTHERAPY | CHRONIC HEPATITIS-C | PHASE-3 | SUSTAINED VIROLOGICAL RESPONSE | THERAPY | PEGINTERFERON ALPHA-2B | DOUBLE-BLIND | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | ONCE-DAILY TMC435 | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | Hepatitis C, Chronic - ethnology | Secondary Prevention | Recombinant Proteins - adverse effects | Simeprevir - adverse effects | Simeprevir - administration & dosage | Ribavirin - administration & dosage | Female | Hepacivirus - drug effects | Drug Administration Schedule | RNA, Viral - analysis | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Interferon-alpha - adverse effects | Viral Load - drug effects | Viral Load - methods | Genetic aspects | Protease inhibitors | Hepatitis C | Proteases | Health aspects
Journal Article
ANTIVIRAL THERAPY, ISSN 1359-6535, 2019, Volume 24, Issue 1, pp. 35 - 44
Background: Optimal treatment for patients with HCV genotype-3 infection and liver cirrhosis remains a medical priority. Daclatasvir+sofosbuvir and ribavirin... 
INFECTIOUS DISEASES | VIRUS GENOTYPE 3 | HIV-HCV COINFECTION | TMC435 MONOTHERAPY | VIROLOGICAL RESPONSE | VELPATASVIR | VIROLOGY | PLUS SOFOSBUVIR | ANTIVIRAL ACTIVITY | PHARMACOLOGY & PHARMACY | NS5A POLYMORPHISMS | INFECTION | ADVANCED LIVER-DISEASE
Journal Article
Journal Article
Journal Article